The UCSF oncological therapeutics spinout will move from California to Connecticut following a leading investment from state-owned Connecticut Innovations.
OncoSynergy, a US-based oncological therapeutics spinout from University of California, San Francisco (UCSF), has completed a series A round of undisclosed size led by government-owned investment firm Connecticut Innovations.
The deal also featured payment processing platform operator Korea Information & Communication and family office NLabs.
OncoSynergy’s approach combines a therapeutic mode known as the resistance mechanism inhibitor (RMI) with other oncological medications to target several cancerous pathways simultaneously. RMIs have the potential to target both solid tumours and blood-related cancers.
…
